MedCity News March 3, 2025
AbbVie is licensing rights to a drug from Gubra that has encouraging early clinical data in obesity. The once-weekly injectable peptide is a dual agonist of the amylin and calcitonin receptors, both of which play key roles in metabolism.
AbbVie is joining the chase for new obesity drugs, but rather than getting a me-too GLP-1 drug, the pharmaceutical giant is landing rights to a clinical-stage molecule that goes after two novel targets to trigger weight loss.
Under deal terms announced Monday, AbbVie will pay Danish company Gubra $350 million up front for rights to its drug, GUB014295. AbbVie will lead further clinical development as well as commercialization. Gubra could receive up to $1.875 million in milestone payments, plus royalties from...
Today's Sponsors
Today's Sponsor